Psilera’s proprietary Third Eye™ drug screening platform enables our team of computational chemists, data scientists, and biomolecular physicists to work collaboratively to analyze how compounds will interact with the brain long before in-vivo dosing. This optimized process saves both time and resources to focus efforts on advancing only the most effective compounds for treating a specific disease.